Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 2 |
| Introduction | 9 | 1 |
| GBI Research Report Guidance | 9 | 1 |
| Coagulation Disorders Therapeutics Market: Market Overview | 10 | 12 |
| Introduction | 10 | 1 |
| Revenue Forecasts for the Global Coagulation Disorders Market | 11 | 1 |
| Revenue | 11 | 1 |
| Annual Cost of Therapy | 12 | 1 |
| Treatment Usage Pattern | 13 | 2 |
| Diseased Population | 15 | 1 |
| Treatment Seeking Population | 16 | 1 |
| Diagnosed Population | 17 | 1 |
| Prescription Population | 18 | 1 |
| Coagulation Disorders Market Drivers | 19 | 1 |
| Steady Increase in the Prevalence Population, Particularly in the Top Five Countries in Europe | 19 | 1 |
| Rapid Uptake of Recombinant Products due to Better Efficacy, Safety and Convenient Dosing | 19 | 1 |
| Increase in the Prescription Population due to Patent Expiries of Expensive Biologic Drugs, Making Them More Affordable | 20 | 1 |
| Coagulation Disorders Market Restraints | 21 | 1 |
| Low Diagnosed Population as Mild and Moderate Forms of Coagulation Disorders Go Undiagnosed | 21 | 1 |
| Patent Expiries of Major Blockbusters Including Kogenate FS, BeneFIX, NovoSeven, and ReFacto Pose a Threat to Leading Players in the Market | 21 | 1 |
| Sluggish Growth in the Annual Cost of Therapy for Coagulation Disorders is Expected to Drive Down the Growth Rate | 21 | 1 |
| Global Coagulation Disorders Market: Geographical Landscape | 22 | 16 |
| Geographical Break-up | 22 | 2 |
| The US | 24 | 1 |
| Revenue | 24 | 1 |
| Annual Cost of Therapy | 25 | 1 |
| Treatment Usage Patterns | 26 | 1 |
| Diseased Population | 27 | 1 |
| Treatment Seeking Population | 27 | 1 |
| Diagnosed Population | 28 | 1 |
| Prescription Population | 28 | 1 |
| Top Five Countries in Europe | 29 | 1 |
| Revenue | 29 | 1 |
| Annual Cost of Therapy | 30 | 1 |
| Treatment Usage Pattern | 31 | 1 |
| Diseased Population | 32 | 1 |
| Treatment Seeking Population | 32 | 1 |
| Diagnosed Population | 32 | 1 |
| Prescription Population | 33 | 1 |
| Japan | 34 | 1 |
| Revenue | 34 | 1 |
| Annual Cost of Therapy | 35 | 1 |
| Treatment Usage Patterns | 36 | 1 |
| Diseased Population | 37 | 1 |
| Treatment Seeking Population | 37 | 1 |
| Diagnosed Population | 37 | 1 |
| Prescription Population | 37 | 1 |
| Coagulation Disorders Therapeutics Market: Therapeutic Landscape | 38 | 35 |
| Hemophilia A Market | 38 | 1 |
| Introduction | 38 | 3 |
| Revenue | 41 | 2 |
| Geographic Segmentation | 43 | 1 |
| Branded vs. Generics | 44 | 1 |
| Annual Cost of Treatment | 45 | 1 |
| Treatment Flow Algorithm | 46 | 1 |
| Treatment Usage Pattern | 47 | 1 |
| Diseased Population | 48 | 1 |
| Treatment Seeking Population | 48 | 1 |
| Diagnosed Population | 49 | 1 |
| Prescription Population | 49 | 1 |
| Hemophilia B Market | 50 | 1 |
| Introduction | 50 | 3 |
| Revenue | 53 | 1 |
| Geographic Segmentation | 54 | 1 |
| Branded vs. Generics | 55 | 1 |
| Annual Cost of Treatment | 56 | 1 |
| Treatment Flow Algorithm | 57 | 1 |
| Treatment Usage Pattern | 58 | 1 |
| Diseased Population | 59 | 1 |
| Treatment Seeking Population | 59 | 1 |
| Diagnosed Population | 60 | 1 |
| Prescription Population | 60 | 1 |
| von Willebrand Disease (vWD) Market | 60 | 1 |
| Introduction | 60 | 5 |
| Revenue | 65 | 1 |
| Geographic Segmentation | 66 | 1 |
| Branded vs. Generics | 67 | 1 |
| Annual Cost of Treatment | 68 | 1 |
| Treatment Flow Algorithm | 69 | 1 |
| Treatment Usage Pattern | 70 | 1 |
| Diseased Population | 71 | 1 |
| Treatment Seeking Population | 71 | 1 |
| Diagnosed Population | 71 | 1 |
| Prescription Population | 72 | 1 |
| Coagulation Disorders Therapeutics Market to 2017: Pipeline Analysis | 73 | 14 |
| Introduction | 73 | 1 |
| Research and Development Pipeline Hemophilia | 74 | 3 |
| Research and Development Pipeline von Willebrand Disease (vWD) | 77 | 1 |
| Profiles of Key Late-Stage Drugs in the Coagulation Disorders Market | 78 | 1 |
| NecLip-pdFVIII | 78 | 1 |
| Introduction | 78 | 1 |
| Mechanism of Action | 78 | 1 |
| Clinical Trial Management | 78 | 1 |
| Long Acting rFactor VIII | 78 | 1 |
| Introduction | 78 | 1 |
| Mechanism of Action | 78 | 1 |
| Clinical Trial Management | 79 | 1 |
| OBI-1 | 79 | 1 |
| Introduction | 79 | 1 |
| Mechanism of Action | 79 | 1 |
| Clinical Trial Management | 79 | 1 |
| Recombinant Factor IX Fc Fusion Protein (rFIXFc) | 80 | 1 |
| Introduction | 80 | 1 |
| Mechanism of Action | 80 | 1 |
| Clinical Trial Management | 80 | 1 |
| NN7008 | 81 | 1 |
| Introduction | 81 | 1 |
| Mechanism of Action | 81 | 1 |
| Clinical Trial Management | 81 | 1 |
| Human-cl rhFVIII | 81 | 1 |
| Introduction | 81 | 1 |
| Mechanism of Action | 82 | 1 |
| Clinical Trial Management | 82 | 1 |
| BAX 326 | 82 | 1 |
| Introduction | 82 | 1 |
| Mechanism of Action | 82 | 1 |
| Clinical Trial Management | 83 | 1 |
| IB1001 | 83 | 1 |
| Introduction | 83 | 1 |
| Mechanism of Action | 83 | 1 |
| Clinical Trial Management | 83 | 1 |
| NNC-0156-0000-0009 | 84 | 1 |
| Introduction | 84 | 1 |
| Mechanism of Action | 84 | 1 |
| Clinical Trial Management | 84 | 1 |
| Biostate | 84 | 1 |
| Introduction | 84 | 1 |
| Mechanism of Action | 84 | 1 |
| Clinical Trial Management | 85 | 1 |
| Long Acting rFactor IX | 85 | 1 |
| Introduction | 85 | 1 |
| Mechanism of Action | 85 | 1 |
| Clinical Trial Management | 86 | 1 |
| Global Coagulation Disorders Market: Competitive Landscape | 87 | 17 |
| Competitive Profiling | 87 | 1 |
| Baxter International Inc. | 87 | 1 |
| Product Portfolio | 87 | 2 |
| SWOT | 89 | 1 |
| Novo Nordisk A/S | 89 | 1 |
| Product Portfolio | 90 | 1 |
| SWOT | 91 | 1 |
| Pfizer Inc. | 91 | 1 |
| Product Portfolio | 92 | 1 |
| SWOT | 92 | 1 |
| CSL Behring LLC | 93 | 1 |
| Product Portfolio | 93 | 1 |
| SWOT | 94 | 1 |
| Bayer AG | 94 | 1 |
| Product Portfolio | 94 | 1 |
| SWOT | 95 | 1 |
| LFB | 95 | 1 |
| Product Portfolio | 95 | 1 |
| SWOT | 96 | 1 |
| Grifols | 96 | 1 |
| Product Portfolio | 96 | 3 |
| SWOT | 99 | 1 |
| Biotest | 99 | 1 |
| Product Portfolio | 99 | 1 |
| SWOT | 100 | 1 |
| Bio Product Laboratory | 100 | 1 |
| Product Portfolio | 100 | 1 |
| SWOT | 101 | 1 |
| Octapharma | 101 | 1 |
| Product Portfolio | 101 | 2 |
| SWOT | 103 | 1 |
| Global Coagulation Disorders Market: Strategic Consolidations | 104 | 4 |
| Overview | 104 | 1 |
| Baxter International Acquire Hemophilia-Related Assets from Archemix in November 2010 | 105 | 1 |
| Paul Capital Healthcare Acquires Rights to Xyntha from Dyax in April 2010 | 105 | 1 |
| Baxter Healthcare Acquires Rights to AV513 from Avigen in December 2008 | 105 | 1 |
| Bayer HealthCare Enters Into Licensing Agreement with Zilip-Pharma | 105 | 1 |
| Wyeth Enters Into Licensing Agreement with Nautilus Biotech | 106 | 1 |
| Deals by Geography | 106 | 1 |
| Deals by Value ($) | 107 | 1 |
| Global Coagulation Disorders Market: Appendix | 108 | 7 |
| Market Definitions | 108 | 1 |
| Abbreviations | 108 | 1 |
| Research Methodology | 109 | 2 |
| Coverage | 109 | 1 |
| Secondary Research | 109 | 1 |
| Primary Research | 110 | 1 |
| Therapeutic Landscape | 110 | 3 |
| Epidemiology-based Forecasting | 111 | 1 |
| Market Size by Geography | 112 | 1 |
| Geographical Landscape | 113 | 1 |
| Pipeline Analysis | 113 | 1 |
| Competitive Landscape | 113 | 1 |
| Expert Panel Validation | 113 | 1 |
| Contact Us | 113 | 1 |
| Disclaimer | 113 | 1 |
| Sources | 114 | 1 |